1 Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada: Clinical Trial Inspection Planning GCP Information Sessions November 2010
2 Overview GCP Inspection Target Process for selecting the target Factors that may impact the target Site Selection Going Forward
3 GCP Inspection Target Process for selecting the target The objectives for the GCP Compliance Program are outlined in Operational Plan A2.4. The objectives are revised every fiscal year. Currently, 80 clinical trial sites per year are targeted for inspection On average, one inspection is conducted in relation to one CTA. An inspection will assess all parties (e.g., CRO). Each region is assigned a number of inspections based on the resource allocation.
4 GCP Inspection Target (cont d) Factors that may impact the target The complexity of the trial(s) being inspected The number of trials being inspected at one site (i.e., one trial versus multiple trials) The need for a lot of follow-up The need for compliance and enforcement action(s) (e.g., resulting from a NC ) The number of compliance verifications and/or investigations
5 Site Selection Inspection Strategy for Clinical Trials (POL-0030) POL-0030 was developed in consultation with TPD and BGTD. POL-0030 outlined the strategy for the effective and uniform implementation of the CT Regulations. Two phases to the implementation of inspections: A confidence building and voluntary phase Started January 1, A final implementation phase Started January 1, The is responsible for site selection.
6 Site Selection (cont d) Voluntary and Confidence Building Phase Phased-in approach used for the implementation of the inspection program; Inspections were performed upon invitation at sites of Sponsors and QIs; Inspections were limited in number (18) and no formal ratings were issued; Stakeholders acquired an understanding of the inspection process and inspectors gained experience; Inspectees were satisfied with the voluntary and phased-in approach.
7 Site Selection (cont d) "Horizontal" Inspections 5 leading paediatric institutions were inspected in 2003/04; Large university hospitals were inspected in 2004/05; Common quality systems and procedures were assessed, in addition to the selected clinical trials; REB and variety of QIs; This approach had a great impact on the entire center.
8 Site Selection (cont d) REB Assessments ( ) Linked to a specific study; Assessed 34 sites; no formal rating was issued; Assessed REB operations, as per ICH E6, and confirmed conformance by Sponsors to the regulatory requirements involving REBs; The focus was on REB membership, member responsibilities, procedures and records; Canadian standard for REBs is being developed.
9 Site Selection (cont d) Selection Process Lists of approved CTAs are generated by SIPD (Submission and Information Policy Division) for the GCP Compliance Unit in Ottawa The lists are a snapshot in time. The lists include site information. The lists do not include information on enrolment. The GCP Compliance Unit maintains a list of previous and scheduled inspections to avoid duplication. Sites are selected for inspection based on these lists and following the selection criteria.
10 Site Selection (cont d) Selection Criteria (current strategy) Number of clinical trials conducted at the site Number of subjects enrolled in the specified clinical trial Status of the specified clinical trial Number of serious unexpected adverse drug reactions at the clinical trial site Compliance history of the sponsor and/or site Drug(s) involved in the specified clinical trial
11 Site Selection (cont d) Selection Process (cont d) Inspections may be conducted at the following sites: Qualified Investigator (QI) site Sponsor Contract Research Organization (CRO) Site Management Organization (SMO) The majority of inspections are done at the QI site. The Sponsor is ultimately responsible for ensuring adherence to the regulatory requirements, including GCP.
12 Going Forward Vision for a representative site selection that would include: Geographical spread Large centers and small clinics All therapeutic products Different therapeutic areas Different dosage forms Commercial versus non-commercial trials New parties Vulnerable populations (psychiatry, paediatrics, women) Flagged trials Different phases, including placebo trials
13 Going Forward (cont d) Selection Criteria (examples) Number of clinical trials conducted at the site Number of subjects enrolled Number of serious unexpected adverse drug reactions Number of protocol deviations Observations made during past inspections Different therapeutic areas Type of responsible party: Sponsors Qualified Investigators (QI) Central Research Organizations (CROs) Site Management Organizations (SMOs)
14 Going Forward (cont d) Selection Criteria (cont d) Identity of the sponsor Commercial vs non commercial organizations Appropriate balance between pharmaceuticals and biologics, therapeutic class Phase of a clinical trial (e.g., Phase I, bioequivalence study) Geographic spread (big city, small city, rural, etc.) Size of the site (University institutions vs. private clinics) New sponsors, QIs, CROs, SMOs International best practices in other jurisdictions where audits/inspections are conducted
15 Going Forward (cont d) Should also consider Targeted vs random inspections Inspections based on theme(s), trend(s) Inspections of ongoing vs closed clinical trials Regular vs horizontal inspections (e.g., large research institutions) Input from the review Directorates Simultaneous inspections of Sponsor and QI vs partial assessments Increased focus on data validation and BE trials Joint inspections with other regulatory authorities
16 QUESTIONS? Further information available online at: Health Canada Drugs and Health Products Compliance and Enforcement Good Clinical Practices
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
Guidance for Industry Oversight of Clinical Investigations A Risk-Based Approach to Monitoring U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research
Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance ICH April 1996 Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance Additional copies are available from: the Drug
Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
College of Health Sciences Department of Health Master of Public Health Program ***************** Council on Education for Public Health Accreditation Self-Study Report September, 2013 1 WEST CHESTER UNIVERSITY
Eclipsys Sunrise Clinical Manager Enterprise Electronic Medical Record (SCM) and Title 21 Code of Federal Regulations Part 11 (21CFR11) The title 21 code of federal regulations part 11 deals with an institutions
Guidance for IRBs, Clinical Investigators, and Sponsors Considerations When Transferring Clinical Investigation Oversight to Another IRB U.S. Department of Health and Human Services Food and Drug Administration
POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR Tracking of Significant Safety issues in Marketed Drugs -- Use of the DARRTS Tracked Safety Issues Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...2
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
Guidance on Developing Key Performance Indicators and Minimum Data Sets to Monitor Healthcare Quality September 2010 Safer Better Care About the The is the independent Authority which has been established
FDA Report FDA ACTION PLAN TO ENHANCE THE COLLECTION AND AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA August 2014 Table of Contents Introduction and Background... 1 FDA Action Plan to Enhance the Collection
General Principles of Software Validation; Final Guidance for Industry and FDA Staff Document issued on: January 11, 2002 This document supersedes the draft document, "General Principles of Software Validation,
STANDARD OPERATING PROCEDURES FOR CLINICAL INVESTIGATORS Juntra Karbwang and Claire Pattou Final SOP status UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) This
M-IC Comptroller of the Currency Administrator of National Banks January 2001 M Management Table of Contents OVERVIEW... 1 BACKGROUND... 1 Objectives... 2 Regulatory Requirements... 3 Components... 5 OCC
October 2007 Audit of the Province s Management of Vision Contributing to public trust in the provincial government and its organizations through the independent audit of management practices and accountability
Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Chapter 3 Section 3.10 Ministry of the Attorney General Office of the Children s Lawyer Chapter 3 VFM Section 3.10 Background The Children s Lawyer is appointed by the Lieutenant Governor on the recommendation
PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017 I. REVIEW PERFORMANCE GOALS A. NDA/BLA Submissions and Resubmissions B. Original Efficacy Supplements C. Resubmitted
South African Nursing Council (Under the provisions of the Nursing Act, 2005) e-mail: firstname.lastname@example.org web: www.sanc.co.za P O Box 1123, Pretoria, 0001 Republic of South Africa Tel: 012 420-1000 Fax:
Audit of IT Asset Management Report Recommended by the Departmental Audit Committee for approval by the President on Approved by the President on September 4, 2012 e-doc : 3854899 1 Table of Contents EXECUTIVE